Report
EUR 14.10 For Business Accounts Only

Despite a better risk assessment and improving to Neutral, CHINA MEHECO GROUP CTD. remains under pressure

CHINA MEHECO GROUP CTD. (CN), a company active in the Pharmaceuticals industry, improves its market behaviour and slightly increases its general evaluation. The independent financial analyst theScreener just upgraded the stock market behaviour as moderately risky. At a fundamental level, theScreener confirms 1 out of 4 possible stars; the general evaluation is slightly increased to Neutral but the title remains under pressure. As of the analysis date December 6, 2019, the closing price was CNY 12.62 and its target price was estimated at CNY 11.16.
Underlying
China Meheco Group Co. Ltd. Class A

CNTIC Trading is engaged in pharmaceutical trading; import and export of products and technology; development, import and export of high and new technology and related products; international bidding; barter trading, counter trading and transit trading; sale of automobile; and the provision of consignment sale, maintenance and technology services. Through its subsidiaries, Co. is also engaged in the design and construction of botanical garden afforestation projects; pharmaceutical production; and sale of medical equipment.

Provider
TheScreener
TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals.  Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

  • Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization.  theScreener state of art: We provide
  • theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
  • For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded

 

Other Reports on these Companies
Other Reports from TheScreener

ResearchPool Subscriptions

Get the most out of your insights

Get in touch